FDA Extends LDT Comment Period as Reimbursement Issue Lingers

Stakeholders should take the extra month to regroup and demand that the FDA work more closely with CMS and other agencies to ensure that reimbursement policies keep pace with the expected additional regulatory compliance costs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.